Share General Information
Macitentan belongs to a class of drugs called endothelin receptor antagonists, which act to relax the arteries connecting the heart to the lungs. It is used to block the progression of pulmonary arterial hypertension (PAH), a chronic, debilitating lung disease. In PAH, high blood pressure in the lungs may cause shortness of breath and physical limitations, and can lead to death or the need for lung transplantation. In a two-year study, treatment with macitentan was shown to significantly reduce the chances for “worsening events” such as death due to respiratory failure, the need for lung transplantation, and other symptoms indicating the significant progression of the disease.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
Updates About Macitentan
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
